Organic Active Ingredients TRIZ Cases

An anti-transferrin receptor antibody carries DMPK-targeting RNAi into cells, addressing poor uptake, limited blood stability, and non-specific immune stimulation.

Novel Resmetirom crystal forms address low solubility and poor stability through controlled crystallization and drying.

Melatonin changes rumen fermentation and methanogenic bacteria abundance to reduce methane without harmful residues.

NTRK1 G595R and NTRK3 G623R resistance is addressed with fluorine-containing macrocyclic TRK inhibitors.

Chemokines CXCL4, CXCL10, CXCL12, and CCL5 modulate TLR8/9 in pDCs, B cells, and macrophages to balance cytokines and IFN-α.

Schweinfurthin compounds expose calreticulin during immunogenic cell death, while checkpoint inhibitors relieve PD-1/PD-L1 suppression to improve tumor control.

Novel oxindole derivatives inhibit DGAT2 while modulating lipogenic and oxidative gene expression for metabolic disorder treatment.

These heterocyclic compounds inhibit CHK-1 to intensify DNA-damaging chemotherapy in p53-defective tumors while limiting toxicity to normal cells.

Irreversible inhibitors target Pol θ residue Lys2383 to suppress DNA repair, cancer cell proliferation, and therapy resistance.

Substituted heterocyclic compounds modulate serotonergic pathways without fully activating 5-HT2A receptors, aiming to limit adverse events.

A pH 4.5–6.5 terazosin liquid replaces slow-dissolving solids, supporting consistent delivery and 100±10% content for 24 months.

Selective non-competitive mGluR5 antagonism with TT00 targets chronic and osteoarthritis pain in animals while minimizing gastrointestinal and renal toxicity.

Variable chemical substituents tune LRRK2 affinity and selectivity, addressing inadequate treatment options for Parkinson’s and related CNS disorders.

NHE3-targeted compounds reduce intestinal phosphate absorption without dietary restriction, addressing CKD and hyperphosphatemia.

An HSP90 epitope vaccine combines selected peptides and immune adjuvants to address drug-resistant breast cancer and strengthen antitumor responses.

Formula I organic compounds provide a small-molecule route to raise phosphorylated AMPK in cells and improve cellular energy balance.

Covalent binding triggers proteasome-mediated estrogen receptor degradation, supporting prolonged tumor regression and delaying treatment resistance.

Immediate-release Selexipag can produce high Cmax and headache, nausea, and vomiting; controlled release lowers peak exposure to improve tolerability.

A mesylate salt and crystalline form address low acidic solubility, improving bioavailability and supporting large-scale drug production.

Using 2–50 μm estetrol particles with wet granulation, the dosage unit dissolves quickly in saliva for sublingual, buccal, or sublabial absorption.

Modular Grignard, Vilsmeier, protection, and deprotection steps provide a more efficient route to itacitinib and its salts.

Conventional fibrosis treatments can cause serious side effects; isolated Rhodiola small RNAs inhibit fibrosis-related genes in cell and animal models.

Oxidation forms disulfide crosslinks in thiol-modified hyaluronan, avoiding external agents and supporting longer hydrogel residence.

Antibody conjugates bind FOLR1 selectively to deliver therapeutic or diagnostic payloads while limiting exposure to lower-expression normal tissues.

Measuring neurofilament protein in blood, serum, or CSF helps identify effective ALS therapies and monitor disease progression.

Selective compounds target mutant p53 while sparing wild-type protein, restoring tumor suppression through DNA binding and downstream pathways.

Sulfonamide CSK inhibitors selectively block CSK over LCK, promoting TCR phosphorylation to strengthen responses to weak tumor antigens.

Modified fused pyridine derivatives inhibit HIV replication while addressing viral escape and treatment failure caused by drug-resistant strains.

Hydrophilic nucleic acid drugs face kidney and liver clearance; PEG shielding and lipid components support membrane transport, targeting, and storage stability.

Dositinib crystalline form B uses deuterium substitution to sustain EGFR-TKI activity against T790M resistance.

Selective oxabicyclo acid compounds inhibit LPA1 receptor activity, targeting fibrosis in the lung, liver, and kidney.

A calcium salt agent stimulates odontoblast growth and dentin bridge formation to help preserve dental pulp vitality after infection removal.

Existing anti-VTCN1 antibodies may inhibit metastasis without shrinking primary tumors; this case adds antibodies and ADCs that reduce tumor size and growth.

Refractory epilepsy in FCDII and TSC is addressed with FLNA modulators such as PTI-125 to normalize neurons and reduce seizures.

Sotorasib raises TNFR1 surface expression and limits shedding, helping CAR-T cells and anti-PD-1 therapy intensify tumor killing.

One-to-stop codons pre-modify the SARS-CoV-2 genome, enabling attenuated virus production for rapid vaccine development and immune protection.

Non-specific chemotherapy can harm normal cells; LSD1 inhibition targets NF1-mutant biology to reduce tumor growth.

A nuclease-resistant complementary strand and single-strand toehold help control RNA binding, reducing off-target toxicity while preserving antisense activity.

Biomarker and symptom testing identifies sepsis patients suited to antiandrogen therapy, improving efficacy while reducing adverse effects.

A resilient upstream end opens during inhalation for powder airflow and closes afterward to retain the capsule and contain dry powder.

Heat inactivation converts live P. acidilactici into a stable postbiotic that reduces body fat while avoiding antibiotic resistance issues.

The case connects mosaic Y loss in blood cells with cardiac fibrosis and uses TGFβ inhibition to address heart failure risk.

Biomarker testing identifies sepsis patients suited to anti-androgen treatment, targeting immune dysregulation while reducing adverse effects.

Combining anti-PD-L1 antibodies with platinum, taxane, or antimetabolite drugs uses sequential phases to address poor NSCLC outcomes.

Relapsed and metastatic colorectal cancer can exhaust standard options; menin-MLL inhibitors offer a targeted treatment approach for durable response.

Stereoselective reduction of DKCA and hydrogenation produce high-purity non-animal-derived UDCA while limiting hydroxysteroid impurities.

Orodispersible sugar granules deliver cannabinoids without smoking, vaporizing, or water while improving dosage control and taste.

Standard zoledronic acid doses can cause side effects and drug interactions; ultra-low dosing targets ASM and FDPS for retinal disease.

Specific CXCR2 agonist and CXCR4 antagonist dosing selectively mobilizes CD34+ cells while limiting other lineage cells for infusion.

Milk-derived proteins with pI ≥6.8 selectively inhibit canine oral pathogens while minimizing effects on beneficial commensals.

Novel 5-membered heteroarylcarboxamide derivatives overcome insufficient potency and gastrointestinal absorption of existing inhibitors.

Replacing hazardous reagents with borohydride and chlorosilanes reduces safety risks while maintaining optical purity in rosuvastatin sodium synthesis.

Tumescent infusion expands tissue volume 2-5 fold, creating edema that breaks up biofilm reservoirs and kills resistant bacteria without systemic toxicity.

FTY720 disrupts SET-PP2A binding to restore phosphatase activity, eliminating TKI-resistant leukemic stem cells.

A heteroaryl[4,3-c]pyrimidine-5-amine derivative structure provides potent inhibition of A2a receptors with high selectivity.

Morpholine derivatives expand the scope of effective renin inhibitors beyond limited piperidine structures.

Novel marine fungus alkaloids inhibit HSV-1 replication, overcoming drug resistance from conventional nucleoside antivirals.

N-benzyl-N'-arylcarbonylpiperazine derivatives modulate LXR receptors to promote cholesterol efflux and enhance HDL levels.

12-lipoxygenase inhibitors target the inflammatory response mediated by 12-LO to alleviate COVID-19 severity.

HA-aldehyde derivatives react selectively with protein N-termini, resolving low bioconjugation efficiency and side effects from non-specific polymer attachment.

Composite hyaluronic acid hydrogels integrate heat-stable additives to resolve ingredient degradation during sterilization while extending filler duration.

Triazole-ketal-triazole linkers prolong circulation time, reducing toxicity while clearing lipids.

Butanol fractionation isolates catalpol derivatives from Pseudolysimachion rotundum var subintegrum plant material.

A gastro-resistant controlled release dosage form minimizes initial drug release using pH-dependent enteric coatings.

Merging Stachyose with Enzalutamide overcomes drug tolerance to sustain treatment efficacy against castration-resistant prostate cancer.

Formula I compounds inhibit BACE-1 and renin to halt disease progression beyond palliative symptom management.

JAK-STAT pathway inhibitors block pathological signaling to restore muscle strength, correcting morphological abnormalities in congenital myopathies.

Adjusting pH to 8-9 overcomes low water solubility, enabling therapeutic concentrations that inhibit viral replication in the respiratory tract.

Store-operated calcium entry modulation induces apoptosis in melanoma cells, bypassing drug resistance and clinical toxicity associated with targeted therapies.

Formula I compounds modulate NK-3 receptor activity to overcome poor bioavailability and blood-brain barrier penetration limits.

Peptides bind EWS-FLI1 to disrupt RNA Helicase A interactions, resolving disordered protein targeting challenges.

New thiazolopyrimidinone compounds lower mutant huntingtin protein to modify Huntington disease progression beyond symptomatic relief.

CRISPR-Cpf1 ribonucleoprotein complexes edit gamma-globin promoters to increase fetal hemoglobin expression in hematopoietic stem cells.

Isolating specific prenylated polyphenols from Morus roots enhances tyrosinase inhibition, addressing efficacy limits of existing skin whitening agents.

Supercritical CO2 extraction isolates Salvia hispanica seed oil, preventing rancidity through antioxidant stabilization for 12 to 24 months.

Micronized sitagliptin base with alginic acid maintains 90% potency under heat while matching Januvia plasma profiles.

Thiazole derivatives with cationic heads exploit membrane negativity to bypass resistance mechanisms, delivering rapid bactericidal action against MRSA.

Press-coated delayed-release glucocorticoids target morning stiffness by releasing medication during peak IL-6 levels.

Liposomes shield antioxidants from oxidative degradation while enabling transdermal delivery across the stratum corneum barrier.

Multiplex biomarker assay detects angiogenesis factors to predict cancer therapy responsiveness and guide personalized treatment plans.

Bornyl acetate composition inhibits microglia activation and inflammatory factor generation to treat depression without side effects.

Fractional crystallization of diastereomeric salts resolves storage stability and handling contradictions for gamma-glutamyl transpeptidase inhibitors.

Cassia occidentalis extracts reverse glucocorticoid-induced bone loss by stimulating osteoblast activity and restoring skeletal strength.

A film coating composition using brewer's yeast and liver powder enhances the palatability of solid veterinary pharmaceuticals.

Combining ascorbic acid with a quinone compound inhibits Trypanosoma cruzi growth through synergistic oxidative stress mechanisms.

A RASGRP1:APTX gene ratio assay predicts patient response to farnesyltransferase inhibitor combination therapies.

Lipid nanoparticles deliver STING-dependent adjuvants to overcome tumor immunoevasiveness and generate anti-tumor T cell activity.

A novel pyridine derivative compound inhibits RON receptor activity, addressing the lack of selective kinase modulators for cancer and immune-related diseases.

Measuring plaque ammonia and lactic acid levels to quantify cariogenic and arginolytic bacteria populations.

Developing stable plinabulin monohydrate crystals resolves drying degradation and impurity issues.

A propolis and gamma-cyclodextrin inclusion complex enhances solubility and bioavailability of anti-cancer agents.

Acetic acid enables higher API concentrations in C1-3 alkanol spray drying solutions.

Combining an ETAR antagonist with chemical castration to block androgen signaling pathways in prostate cancer treatment.

Inhibiting 15-PGDH prevents corticosteroid-induced prostaglandin degradation, reducing cytotoxicity while maintaining anti-inflammatory efficacy.

Combining a TLR7 inhibitor with prednisolone or hydroxychloroquine reduces Type I Interferon production to treat cutaneous lupus erythematosus.

A sugar-free paracetamol liquid formulation uses polyethylene glycol and xanthan gum to maintain solubility.

Dissolving sildenafil citrate in an ethanol-water carrier resolves low solubility constraints to achieve faster therapeutic onset and reduced side effects.

A sonic hedgehog signaling pathway activator stimulates nucleus pulposus cell proliferation to regenerate degenerated spinal disc tissue.

Isoquinoline-corticosteroid conjugates reduce intraocular pressure while maintaining anti-inflammatory efficacy.

Citric acid buffering maintains pH 3.0 to 4.0, enabling room temperature stability without antioxidants or complex oxygen exclusion.

Selective laser sintering produces diverse solid pharmaceutical dosage forms including films and tablets, overcoming FDM limitations.

A fumarate hydrate crystal form of a dihydropyrido[2,3-d]pyrimidine derivative inhibits AKT kinase activity.

Targeting NTRK gene fusions with specific inhibitors reduces tumor burden and manages disease progression in metastatic neuroendocrine tumors.

Hydrogenated alkyl ketene dimers act as latent dispersants in paper coatings.

Controlled cooling of JAK kinase inhibitor bisulfate in organic solvents yields crystal form II with improved stability under high temperature and humidity.

Calcium mediates manganese release in calmangafodipir to reduce neurotoxicity while maintaining antioxidant efficacy for oxidative stress treatment.

Replacing invasive surgery with mifepristone receptor antagonism prevents high-grade serous ovarian and breast cancers while preserving reproductive function.

Administering specific human milk oligosaccharides modulates gut microbiota to induce mucosal healing while avoiding adverse side effects from immunomodulators.

A water-soluble adhesive coating delivers rapamycin to inhibit neointimal hyperplasia and restenosis in small diameter vessels.

Pyridinone derivatives inhibit D-amino acid oxidase to elevate D-serine levels, resolving excitotoxicity risks from direct NMDA receptor agonists.

A YAP/TAZ-TEAD interaction inhibitor disrupts the Hippo signaling pathway to suppress tumor growth.

Segmenting PMOs onto CPPs via cleavable linkers reduces steric hindrance and toxicity while improving exon skipping efficacy.

Succinate buffering reduces degradation product formation in caspofungin acetate salt compositions compared to traditional acetate systems.

A Nimorazole tablet disintegrates in water to form a dispersion suitable for tube administration.

An AGT RNA interference agent silences angiotensinogen mRNA to regulate blood pressure.

Selective PDE10 inhibition by aryloxymethyl cyclopropane derivatives increases cyclic nucleotide levels, addressing schizophrenia treatment limitations.

Spray melt droplets into a fluidized bed to form uniform globular particles, eliminating solvent residues and irregular shapes from comminution.

Combines molecular oxygen with hyaluronic acid to stimulate microcirculation and improve vaginal lubrication.

Biodegradable ureteral stents impregnated with anti-cancer drugs via supercritical fluid CO2 technology provide sustained therapeutic release.

Upregulating TNAP and downregulating ANK converts intervertebral discs to bone, avoiding invasive spinal fusion surgery.

A vaginal hydrogel film delivers therapeutics via sustained release, resolving messiness and pH imbalance from traditional creams.

A 64Zn-enriched zinc composition reduces body weight and normalizes metabolic parameters.

ADAMTS13 agonists prevent thrombotic microangiopathy by cleaving von Willebrand factor multimers, mitigating renal damage and platelet consumption.

HAPLN1 protein activates TGF-β receptors in chondrocytes to regenerate cartilage, replacing unsafe animal-derived collagen treatments.

Selective JAK1 inhibitors overcome limited therapeutic options by targeting CSF3R mutations in chronic neutrophilic and atypical chronic myeloid leukemia.

A single-dosed nasal rinse uses water-soluble anti-infective substances to incapacitate germs in the nasal zone.

Heterocyclicalkyl derivatives target HDAC 6 to reduce side effects from non-selective inhibition.

Silicon-heteroatom cores enable pH-dependent hydrolysis for targeted payload release.

Substituted triazolones selectively inhibit prolyl endopeptidase, reducing PGP-driven neutrophil recruitment and inflammation in COPD.

Combining vancomycin and checkpoint inhibitors modulates bile acid composition to activate NKT cells, reducing liver tumor growth and metastasis.

Antisense oligonucleotides bind to SOD1 pre-mRNA to induce exon skipping, reducing toxic protein levels in amyotrophic lateral sclerosis.

Amino acid-derived silyl polymers form pressure-sensitive adhesives that adhere to skin while storing active agents.

Cycloalkyl-substituted pleuromutilin derivatives enhance water solubility through structural modification.

Segmented FMR1 analysis identifies low-expression alleles, enabling targeted enhancer administration that rescues embryos from BRCA1-associated lethality.

Combining [6]-paradol and bisabolol in a specific weight ratio achieves synergistic irritation reduction while maintaining formulation stability.

Deuterated ranolazine derivatives expand angina treatment options by enhancing metabolic stability while managing synthesis complexity.

Formula I piperazine derivatives inhibit gluconeogenesis to reduce blood sugar levels in diabetic models.

Replacing organic solvents with ethanol and lyophilization simplifies hospital preparation while maintaining production reliability.

Formula I compounds inhibit Bruton's tyrosine kinase activity via localized binding, reducing bone erosion in rheumatoid arthritis.

PROTAC compounds degrade CAMKK2 via the ubiquitin-proteasome pathway, addressing limited specificity of conventional inhibitors.

Measuring FSHR expression levels in tumor samples predicts patient responsiveness to tyrosine kinase inhibitors, reducing unnecessary side effects and costs.